Hemicentin (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Hemicentin-1 (HMCN1/Fibulin-6, UniProt Q96RW7) expressed in HEK293 cells. Suitable for extracellular matrix interaction studies, TGF-β pathway assays, podocyte biology research, and antibody validation.
Expression system
HEK293
Cat. #
REC-Hemicentin

In stock

SKU
REC-Hemicentin
$498.00

Target Overview

Hemicentin-1 (UniProt Q96RW7; gene HMCN1) is a large, secreted extracellular matrix glycoprotein of the fibulin family, also catalogued as Fibulin-6. The full-length human protein spans 5,635 amino acid residues, placing it among the largest members of the fibulin superfamily. It localises to the basement membrane compartment of the extracellular space, where it participates in matrix organisation and cell-junction architecture. This recombinant is produced in HEK293 mammalian cells, a system that supports the folding and glycosylation patterns characteristic of secreted extracellular matrix proteins. Mammalian expression is particularly relevant for Hemicentin-1 given its extensive domain architecture — including immunoglobulin-like repeats and EGF-like domains — whose functional integrity depends on native disulfide bond formation and glycan decoration. Researchers use this recombinant in several contexts. In cell biology, it serves as a defined substrate or soluble ligand to probe podocyte cytoskeletal remodelling downstream of TGF-β signalling, including measurement of F-actin reorganisation, cell shape changes, and downstream effector phosphorylation. In matrix biology, it is used to study basement membrane assembly, laminin and collagen IV interaction networks, and epithelial cell-junction organisation in co-culture systems. In cardiac research, it is employed to examine fibroblast migration assays relevant to myocardial remodelling models. This recombinant also functions as a validated positive control antigen for antibody characterisation experiments. Researchers running Western blot or IHC validation of anti-HMCN1 antibodies can pair this recombinant directly with the Triple Point Biologics matched antibody (SKU: RP-Hemicentin) to confirm band identity, titre, and cross-reactivity against recombinant versus endogenous material.

Background

Hemicentin-1 (HMCN1) is a conserved, secreted extracellular matrix protein of the fibulin superfamily, characterised by a tandem array of immunoglobulin-like repeats flanked by EGF-like and calcium-binding domains. It is expressed in basement membrane-rich tissues including kidney glomeruli, skin dermal-epidermal junctions, and the developing heart. Its structural role is to organise and stabilise flexible adhesive junctions between cell layers and the underlying basement membrane, rather than acting as a classical signalling ligand. In podocyte biology, Hemicentin-1 has been investigated as a downstream effector of TGF-β signalling. Published data indicate it participates in TGF-β-mediated rearrangement of the podocyte cytoskeleton, driving reduction of F-actin fibres alongside broadening and elongation of podocyte cell bodies — changes that are relevant to models of glomerular injury studied in kidney research laboratories. Hemicentin-1 has attracted particular research attention in the context of inherited skin fragility disorders. Bergson et al. (2025, J Exp Med) reported that heterozygous HMCN1 variants aggravate the epidermolysis bullosa simplex (EBS) phenotype in patients carrying primary KRT5/KRT14 mutations, establishing HMCN1 as a genetic modifier acting at the dermal-epidermal junction. A companion commentary by Coulombe (2025, J Exp Med) discussed the broader implications of such "second hit" mechanisms in dominantly inherited genodermatoses, reinforcing the value of well-characterised HMCN1 recombinant protein for in vitro binding and structural studies of this junction. In cardiac biology, HMCN1 expression has been associated with myocardial remodelling contexts, where it may influence cardiac fibroblast migration — a process studied in models of ventricular development and remodelling. HMCN1 has also appeared in transcriptomic datasets from models of intermittent hypoxia-induced cognitive dysfunction (Miyo et al., 2025, Int J Mol Sci), pointing to expression changes in hippocampal tissue, though the mechanistic role of Hemicentin-1 in neural extracellular matrix biology remains an open area of investigation. Across these research areas, a recombinant Hemicentin-1 protein of defined sequence and mammalian glycosylation provides a tractable tool for in vitro binding experiments, cell treatment assays, and antibody validation against a structurally representative antigen — supporting research into the biology of basement membrane organisation and its perturbation in disease models.

Applications

  • Antibody validation positive control: confirm band identity and titre of anti-HMCN1 antibodies on Western blot (pairs with Triple Point Biologics RP-Hemicentin)
  • IHC antigen standard: spike into tissue lysate panels to verify anti-HMCN1 antibody specificity in immunohistochemistry workflows
  • TGF-β cytoskeletal remodelling assay: add as exogenous substrate or treatment ligand in podocyte F-actin reorganisation experiments
  • Basement membrane protein interaction study: use as bait in solid-phase binding assays with laminin, collagen IV, or nidogen
  • Cardiac fibroblast migration assay: coat migration chambers or include in conditioned-medium reconstitution experiments to assess effect on fibroblast motility
  • Cell morphology assay: treat cultured podocytes or epithelial cells to assess dose-dependent changes in cell spreading, elongation, and junction architecture
  • ELISA capture or detection standard: use as calibration antigen for sandwich ELISA development measuring endogenous HMCN1 in conditioned medium or serum samples

References

  1. Bergson S et al. HMCN1 variants aggravate epidermolysis bullosa simplex phenotype. J Exp Med. 2025. doi:10.1084/jem.20240827 PMID: 39976600
  2. Coulombe PA. A "second hit" impacts disease severity in a dominantly inherited genetic skin disorder. J Exp Med. 2025. doi:10.1084/jem.20242377 PMID: 39976599
  3. Miyo K et al. Intermittent Hypoxia Induces Cognitive Dysfunction and Hippocampal Gene Expression Changes in a Mouse Model of Obstructive Sleep Apnea. Int J Mol Sci. 2025. doi:10.3390/ijms26157495 PMID: 40806623
  4. Wang L et al. Ets1-regulated endothelial-secreted factors promote compact myocardial growth and contribute to the pathogenesis of ventricular non-compaction. Cardiovasc Res. 2026. doi:10.1093/cvr/cvaf264 PMID: 41329636

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; basement membrane

Frequently Asked Questions

What molecular weight does recombinant Hemicentin-1 run at on SDS-PAGE and Western blot?

Full-length human Hemicentin-1 (HMCN1, UniProt Q96RW7) has a predicted molecular weight of approximately 614 kDa from its 5,635 amino acid sequence. On SDS-PAGE under reducing conditions, the recombinant produced in HEK293 cells typically migrates anomalously above 460 kDa due to extensive N- and O-linked glycosylation inherent to mammalian-expressed ECM proteins. Do not expect a sharp, tight band at the sequence-predicted MW — diffuse, smeared signal in the 460–700 kDa range is normal and reflects native-like glycan decoration rather than degradation or aggregation.

Is this recombinant full-length Hemicentin-1 or a fragment, and which isoform does it correspond to?

This recombinant corresponds to the canonical full-length isoform 1 of human Hemicentin-1 (UniProt Q96RW7-1, 5,635 aa), expressed in HEK293 cells with a signal peptide removed post-translationally to yield the secreted mature form. No further proteolytic processing sites are definitively mapped in the literature for human Hemicentin-1 under physiological conditions. The product is supplied as the secreted, glycosylated ectodomain in solution. Researchers working with shorter constructs or specific domain fragments (e.g., isolated Ig-like repeats) should note this preparation covers the full extracellular span.

What is the domain architecture of Hemicentin-1 and does it bind or cleave any substrates?

Hemicentin-1 is not a protease and does not cleave substrates. Its domain architecture includes an N-terminal fibulin-type module, 48 tandem immunoglobulin-like repeats, multiple EGF-like domains, and a C-terminal fibulin module — collectively mediating protein–protein and protein–matrix interactions rather than catalytic activity. Functionally, it organises basement membrane architecture and stabilises cell–cell junctions. In binding assays, it interacts with other ECM components such as fibronectin and perlecan. Use this recombinant as a coating substrate, soluble ligand, or interaction partner in pull-down and ELISA-based binding experiments rather than enzymatic activity assays.

What concentration should I use to coat plates or use as a substrate for cell adhesion assays with recombinant Hemicentin-1?

For cell adhesion and spreading assays, a starting coating concentration of 2–10 µg/mL in PBS (applied overnight at 4°C, then blocked with 1% BSA) is a reasonable initial range. Given Hemicentin-1's role as a large ECM scaffold protein, concentrations at the lower end (2–5 µg/mL) often saturate binding sites on standard tissue-culture plastic; titrate per cell type. For pull-down or co-immunoprecipitation experiments using this protein as bait, 1–5 µg per reaction in 50 mM Tris-HCl pH 7.5, 150 mM NaCl is a practical starting point consistent with the supplied storage buffer.

What buffer is recombinant Hemicentin-1 supplied in and how should I dilute it for experiments?

Recombinant Hemicentin-1 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol. This buffer is compatible with most cell-based and biochemical assays without further exchange. For cell-based work, dilute directly into serum-free culture medium; the glycerol concentration drops to negligible levels at working dilutions (≥1:10). If your assay is sensitive to glycerol (e.g., SPR/BLI binding kinetics), buffer-exchange via centrifugal ultrafiltration (100 kDa MWCO) into assay-appropriate buffer is recommended. Avoid PBS alone for long-term diluted stock storage — the Tris-NaCl-glycerol formulation maintains protein stability at -20°C.

How should I store recombinant Hemicentin-1 and what is its shelf life after thawing?

Store at -20°C in single-use aliquots as supplied. Avoid repeated freeze-thaw cycles, which risk aggregation of this large glycoprotein (>460 kDa on gel). Once thawed, keep on ice and use within 24 hours; do not refreeze. Aliquots stored continuously at -20°C are stable for at least 12 months from the date of receipt when kept in the original formulation (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol). Adding a carrier protein such as 0.1% BSA is not necessary given the glycerol-containing buffer, but may help at very low working concentrations (<0.1 µg/mL).

Can I use recombinant Hemicentin-1 as a Western blot positive control for the RP-Hemicentin rabbit polyclonal antibody?

Yes — this is a validated pairing. Recombinant Hemicentin-1 (REC-Hemicentin) was used during the development and lot-release testing of the matched RP-Hemicentin rabbit polyclonal antibody, confirming band detection by Western blot. Load 50–200 ng of recombinant per lane on a 3–8% Tris-acetate or gradient gel (standard SDS-PAGE resolving gels are inadequate for a protein migrating above 460 kDa). Expect a diffuse band in the 460–700 kDa region under reducing conditions. This lane serves as a clean, cell-lysate-free positive control for antibody validation experiments and troubleshooting signal in tissue lysates.

How much recombinant Hemicentin-1 should I load for a Western blot positive control, and what gel percentage do you recommend?

Load 100–200 ng per lane as an initial titration; signal intensity can be adjusted to 50 ng if background is high. Because Hemicentin-1 migrates well above 250 kDa, use a 3–8% Tris-acetate polyacrylamide gel or a 4–12% gradient gel run at low voltage to allow adequate separation in the high-MW range. Pair with the RP-Hemicentin antibody (SKU: RP-Hemicentin) at the manufacturer's recommended dilution. Transfer efficiency for proteins of this size is the most common bottleneck — use a wet-tank transfer system with 0.025% SDS added to transfer buffer, and a PVDF membrane (0.45 µm pore size).

Validation imagery coming soon

Western blot validation figures for REC-Hemicentin will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →